These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 20947617)
1. Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Zhang F; Tagen M; Throm S; Mallari J; Miller L; Guy RK; Dyer MA; Williams RT; Roussel MF; Nemeth K; Zhu F; Zhang J; Lu M; Panetta JC; Boulos N; Stewart CF Drug Metab Dispos; 2011 Jan; 39(1):15-21. PubMed ID: 20947617 [TBL] [Abstract][Full Text] [Related]
2. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. Brennan RC; Federico S; Bradley C; Zhang J; Flores-Otero J; Wilson M; Stewart C; Zhu F; Guy K; Dyer MA Cancer Res; 2011 Jun; 71(12):4205-13. PubMed ID: 21515735 [TBL] [Abstract][Full Text] [Related]
3. Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). Bai F; Zhu F; Tagen M; Miller L; Owens TS; Mallari J; Derrick E; Zhang F; Stewart CF J Pharm Biomed Anal; 2010 Mar; 51(4):915-20. PubMed ID: 19931997 [TBL] [Abstract][Full Text] [Related]
4. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Michaelis M; Rothweiler F; Klassert D; von Deimling A; Weber K; Fehse B; Kammerer B; Doerr HW; Cinatl J Cancer Res; 2009 Jan; 69(2):416-21. PubMed ID: 19147553 [TBL] [Abstract][Full Text] [Related]
5. Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner. Shuvalov O; Kizenko A; Shakirova A; Fedorova O; Petukhov A; Aksenov N; Vasileva E; Daks A; Barlev N Biochem Biophys Res Commun; 2018 Jan; 495(1):1233-1239. PubMed ID: 29175211 [TBL] [Abstract][Full Text] [Related]
6. Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model. Tonsing-Carter E; Bailey BJ; Saadatzadeh MR; Ding J; Wang H; Sinn AL; Peterman KM; Spragins TK; Silver JM; Sprouse AA; Georgiadis TM; Gunter TZ; Long EC; Minto RE; Marchal CC; Batuello CN; Safa AR; Hanenberg H; Territo PR; Sandusky GE; Mayo LD; Eischen CM; Shannon HE; Pollok KE Mol Cancer Ther; 2015 Dec; 14(12):2850-63. PubMed ID: 26494859 [TBL] [Abstract][Full Text] [Related]
7. Targeted nutlin-3a loaded nanoparticles inhibiting p53-MDM2 interaction: novel strategy for breast cancer therapy. Das M; Dilnawaz F; Sahoo SK Nanomedicine (Lond); 2011 Apr; 6(3):489-507. PubMed ID: 21542687 [TBL] [Abstract][Full Text] [Related]
8. The hydrophobically-tagged MDM2-p53 interaction inhibitor Nutlin-3a-HT is more potent against tumor cells than Nutlin-3a. Nietzold F; Rubner S; Berg T Chem Commun (Camb); 2019 Nov; 55(95):14351-14354. PubMed ID: 31720601 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807 [TBL] [Abstract][Full Text] [Related]
10. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514 [TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Elison JR; Cobrinik D; Claros N; Abramson DH; Lee TC Arch Ophthalmol; 2006 Sep; 124(9):1269-75. PubMed ID: 16966622 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546 [TBL] [Abstract][Full Text] [Related]